Division of Paediatric Endocrinology and Diabetology, Centre of Child and Adolescent Medicine, Justus Liebig University, Giessen, Germany.
Institute of Epidemiology and Medical Biometry (ZIBMT), Ulm University, Ulm, Germany.
Diabetologia. 2022 Jul;65(7):1108-1118. doi: 10.1007/s00125-022-05701-w. Epub 2022 Apr 30.
Screening for coeliac disease in asymptomatic children with new-onset type 1 diabetes is controversial. The aim of this study was to analyse whether the confirmation of coeliac disease in children with new-onset type 1 diabetes and positive screening results can be postponed.
This was a multicentre population-based cohort study based on the German/Austrian/Swiss/Luxembourgian Prospective Diabetes Follow-up Registry (Diabetes Patienten Verlaufsdokumentation [DPV]). Participants aged ≤18 years diagnosed with type 1 diabetes between 1995 and June 2021 and with elevated IgA tissue transglutaminase antibodies (anti-tTGA) at diabetes onset on screening for coeliac disease were included. We compared outcomes of participants with a diabetes duration of more than 1 year between those in whom coeliac disease was confirmed histologically within the first 6 months and those in whom coeliac disease was confirmed between 6 and 36 months after diabetes diagnosis.
Of 92,278 children and adolescents with a diagnosis of type 1 diabetes, 26,952 (29.2%) had documented anti-tTGA data at diabetes onset. Of these, 2340 (8.7%) had an elevated anti-tTGA level. Individuals who screened positive were younger (median age 9.0 vs 9.8 years, p<0.001) and more often female (53.1% vs 44.4%, p<0.001). A total of 533 participants (22.8% of those who screened positive) had a documented biopsy, of whom 444 had documented histological confirmation of coeliac disease. Of 411 participants with biopsy-proven coeliac disease within the first 36 months of diabetes and follow-up data, histological confirmation was performed in 264 (64.2%) within the first 6 months and in 147 (35.8%) between 6 and 36 months after diabetes onset. At follow-up (median diabetes duration 5.3 years and 5.1 years, respectively), estimated median HbA levels (62.8 mmol/mol vs 62.2 mmol/mol [7.9% vs 7.8%]), cardiovascular risk markers (lipids, rate of microalbuminuria, blood pressure), rates of acute diabetes complications (diabetic ketoacidosis, severe hypoglycaemia) and the proportions of participants reaching anti-tTGA levels within the normal range did not differ between groups. Participants with delayed histological confirmation of coeliac disease showed no negative effects on growth or weight gain during the observation period.
Our study suggests that the histological confirmation of coeliac disease in asymptomatic individuals with new-onset type 1 diabetes could be postponed.
在无症状的初发 1 型糖尿病患儿中筛查乳糜泻存在争议。本研究旨在分析初发 1 型糖尿病且筛查结果阳性患儿中乳糜泻的确诊是否可以推迟。
这是一项基于德国/奥地利/瑞士/卢森堡前瞻性糖尿病随访登记处(Diabetes Patienten Verlaufsdokumentation [DPV])的多中心基于人群的队列研究。纳入年龄≤18 岁、1995 年至 2021 年 6 月期间诊断为 1 型糖尿病且在筛查乳糜泻时初发时 IgA 组织转谷氨酰胺酶抗体(抗-tTGA)升高的参与者。我们比较了糖尿病病程超过 1 年的参与者中,在初诊后 6 个月内经组织学确诊乳糜泻者和在糖尿病诊断后 6 至 36 个月内确诊乳糜泻者之间的结局。
在诊断为 1 型糖尿病的 92278 名儿童和青少年中,有 26952 名(29.2%)在初发时记录了抗-tTGA 数据。其中,2340 名(8.7%)抗-tTGA 水平升高。筛查阳性者年龄更小(中位数 9.0 岁 vs 9.8 岁,p<0.001)且更常为女性(53.1% vs 44.4%,p<0.001)。共有 533 名参与者(筛查阳性者的 22.8%)进行了记录的活检,其中 444 名有记录的组织学证实为乳糜泻。在糖尿病发病后 36 个月内有记录的活检且有随访数据的 411 名参与者中,264 名(64.2%)在初诊后 6 个月内进行了组织学确认,147 名(35.8%)在糖尿病发病后 6 至 36 个月内进行了组织学确认。在随访时(中位糖尿病病程分别为 5.3 年和 5.1 年),估计的中位 HbA 水平(62.8 mmol/mol vs 62.2 mmol/mol [7.9% vs 7.8%])、心血管风险标志物(血脂、微量白蛋白尿发生率、血压)、急性糖尿病并发症(糖尿病酮症酸中毒、严重低血糖)的发生率以及达到抗-tTGA 正常范围的参与者比例在两组间均无差异。乳糜泻的组织学确认延迟的参与者在观察期间的生长和体重增加方面没有显示出任何负面影响。
本研究提示,在初发 1 型糖尿病无症状个体中,乳糜泻的组织学确诊可推迟。